Company / PP&E (Net)
Tvardi Therapeutics, Inc. PP&E (Net) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.3M
FY2023
5-year range
$426.0K / $3.3M
FY2019-FY2023
Trend
+679.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) changed +680% YoY in FY2023, a notable deviation from the 8-year average annual change of +75%.
Based on SEC 10-K filings.
$3M in FY2023 with a 5-year CAGR of +30.4%.
Improved from $631,000 to $3M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +58.1%
- 5-Year CAGR
- +30.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +30.4%, indicating consistent growth.
- In FY2023, pp&e (net) increased 679.8% year-over-year.
- Lowest pp&e (net) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $3.3M | +679.8% |
| FY2022 | $426.0K | -32.5% |
| FY2021 | $631.0K | -24.9% |
| FY2020 | $840.0K | +20.0% |
| FY2019 | $700.0K | -20.5% |
| FY2018 | $880.0K | -25.2% |
| FY2017 | $1.2M | -27.1% |
| FY2016 | $1.6M | +27.8% |
| FY2015 | $1.3M | -39.4% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026